Bioventix PLC (LON:BVXP) had its target price raised by investment analysts at FinnCap from GBX 1,350 ($16.45) to GBX 1,450 ($17.67) in a report released on Monday. The brokerage presently has a “corporate” rating on the biotechnology company’s stock. FinnCap’s target price points to a potential downside of 0.85% from the company’s current price.

Bioventix PLC (LON:BVXP) traded up 0.86% during mid-day trading on Monday, hitting GBX 1462.50. The company had a trading volume of 17,734 shares. Bioventix PLC has a 12-month low of GBX 899.50 and a 12-month high of GBX 1,600.00. The firm’s market capitalization is GBX 73.87 million. The company’s 50 day moving average price is GBX 1,169.99 and its 200-day moving average price is GBX 1,047.77.

The firm also recently declared a dividend, which will be paid on Friday, November 11th. Shareholders of record on Thursday, October 27th will be issued a dividend of GBX 46 ($0.56) per share. This is an increase from Bioventix PLC’s previous dividend of $16.50. This represents a yield of 3.15%. The ex-dividend date of this dividend is Thursday, October 27th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About Bioventix PLC

Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

Receive News & Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related companies with's FREE daily email newsletter.